GIP (glucose-dependent insulinotropic polypeptide) is the second major incretin hormone alongside GLP-1. Released by K-cells in the duodenum after eating, GIP stimulates glucose-dependent insulin secretion. Tirzepatide is the first marketed drug to activate both GIP and GLP-1 receptors. The combination produces larger glucose-lowering and weight-loss effects than GLP-1 monotherapy alone (per SURPASS-2 head-to-head).
Also known as
glucose-dependent insulinotropic polypeptide
Drugs in this category
Related terms
- GLP-1
- Glucagon-like peptide-1 receptor agonist — class of drugs that mimic a gut hormone to reduce appetite and slow stomach emptying.
- Tirzepatide
- Dual GIP/GLP-1 receptor agonist; active ingredient in Mounjaro and Zepbound.
- Incretin
- Gut hormone (GLP-1 or GIP) that stimulates insulin secretion in response to oral glucose.